Literature DB >> 3972082

In vitro amiodarone protein binding and its interaction with warfarin.

P Neyroz, M Bonati.   

Abstract

The binding of amiodarone to human plasma protein and to bovine serum albumin was studied by three different methods, ultracentrifugation, equilibrium dialysis and fluorescence spectroscopy. The fraction of amiodarone bound to plasma protein amounted to 96.3%. The changes in the binding properties of 1-anilino-naphthalene-8-sulfonate for bovine serum albumin using warfarin and amiodarone as independent inhibitors were analyzed in terms of binding site specificity. The findings indicated that amiodarone and warfarin have two different binding sites on bovine serum albumin, so a noncompetitive inhibition mechanism was indicated. On the basis of our data we cannot exclude other mechanisms of interaction besides direct displacement of one drug by another; nevertheless, metabolite interference between amiodarone and coagulation cofactors may better explain the enhancement of warfarin's pharmacological action in association with amiodarone.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3972082     DOI: 10.1007/bf02004505

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  18 in total

1.  The binding of organic ions by proteins; competition phenomena and denaturation effects.

Authors:  I M KLOTZ; H TRIWUSH; F M WALKER
Journal:  J Am Chem Soc       Date:  1948-09       Impact factor: 15.419

2.  Phenylbutazone-sodium warfarin binding using a fluorescent probe technique.

Authors:  H W Jun; L A Luzzi; P L Hsu
Journal:  J Pharm Sci       Date:  1972-11       Impact factor: 3.534

3.  Side effects of long-term amiodarone therapy.

Authors:  L Harris; W J McKenna; E Rowland; D W Holt; G C Storey; D M Krikler
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

4.  Dangers of amiodarone and anticoagulant treatment.

Authors:  A Rees; J J Dalal; P G Reid; A H Henderson; M J Lewis
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-30

Review 5.  Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone.

Authors:  F I Marcus; G H Fontaine; R Frank; Y Grosgogeat
Journal:  Am Heart J       Date:  1981-04       Impact factor: 4.749

6.  Pharmacokinetics of amiodarone after intravenous and oral administration.

Authors:  F Andreasen; H Agerbaek; P Bjerregaard; H Gøtzsche
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

8.  Amiodarone kinetics after oral doses.

Authors:  R Kannan; K Nademanee; J A Hendrickson; H J Rostami; B N Singh
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

9.  Pharmacokinetics of amiodarone in man.

Authors:  E Riva; M Gerna; R Latini; P Giani; A Volpi; A Maggioni
Journal:  J Cardiovasc Pharmacol       Date:  1982 Mar-Apr       Impact factor: 3.105

10.  Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

Authors:  J J Heger; E N Prystowsky; W M Jackman; G V Naccarelli; K A Warfel; R L Rinkenberger; D P Zipes
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

View more
  3 in total

Review 1.  Pharmacokinetic drug interactions with amiodarone.

Authors:  L J Lesko
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

3.  Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.

Authors:  M E Veronese; S McLean; R Hendriks
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.